gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma

Tumor-reactive CD4+T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts

(2010) Sergio A. Quezada et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treatment of Metastatic Melanoma Using Interleukin-2 Alone or in Conjunction with Vaccines

(2008) F. O. Smith et al.   CLINICAL CANCER RESEARCH

Three Phase II Cytokine Working Group Trials of gp100 (210M) Peptide Plus High-Dose Interleukin-2 in Patients With HLA-A2–Positive Advanced Melanoma

(2008) Jeffrey A. Sosman et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumor-Infiltrating FOXP3+ T Regulatory Cells Show Strong Prognostic Significance in Colorectal Cancer

(2008) Paul Salama et al.   JOURNAL OF CLINICAL ONCOLOGY

CTLA-4 blockade increases IFN -producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

(2008) C. I. Liakou et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA